山东大学耳鼻喉眼学报 ›› 2025, Vol. 39 ›› Issue (5): 125-131.doi: 10.6040/j.issn.1673-3770.0.2023.339
• 综述 • 上一篇
王盛1,李银丹2,杨金姬2
WANG Sheng1, LI Yindan2, YANG Jinji2
摘要: 鼻咽癌是一种发生于鼻咽黏膜的上皮性恶性肿瘤,多数患者伴有潜伏性EB病毒感染,在亚洲人群中较为常见。在鼻咽癌中,微小RNA(microRNA, miRNA)同时具有抑癌基因和致癌基因的功能,miRNA通过调控参与多种细胞过程和通路的特异靶基因,在鼻咽癌的发病机制中发挥重要作用。miRNAs的失调与鼻咽癌患者预后和临床结果有关,miRNA及其靶基因可作为治疗靶点改善鼻咽癌对放疗和化疗的敏感性。因此,了解miRNA的重要特征与其在鼻咽癌诊断、预后评估及治疗中的应用具有重要的临床价值。
中图分类号:
| [1] Huang HG, Yao YY, Deng XY, et al. Immunotherapy for nasopharyngeal carcinoma: current status and prospects(Review)[J]. Int J Oncol, 2023, 63(2): 97. doi:10.3892/ijo.2023.5545 [2] Howlett J, Hamilton S, Ye A, et al. Treatment and outcomes of nasopharyngeal carcinoma in a unique non-endemic population[J]. Oral Oncol, 2021, 114: 105182. doi:10.1016/j.oraloncology.2021.105182 [3] Yuan L, Li SB, Chen QY, et al. EBV infection-induced GPX4 promotes chemoresistance and tumor progression in nasopharyngeal carcinoma[J]. Cell Death Differ, 2022, 29(8): 1513-1527. doi:10.1038/s41418-022-00939-8 [4] Guo FF, Chen DY, Zong ZY, et al. Comprehensive analysis of aberrantly expressed circRNAs, mRNAs and lncRNAs in patients with nasopharyngeal carcinoma[J]. J Clin Lab Anal, 2023, 37(2): e24836. doi:10.1002/jcla.24836 [5] Thakur A, Kumar M. Integration of human and viral miRNAs in epstein-barr virus-associated tumors and implications for drug repurposing[J]. OMICS, 2023, 27(3): 93-108. doi:10.1089/omi.2023.0005 [6] 涂巧铃,李玉凤,彭军. 鼻咽癌中抗PD-L1/PD-1治疗及非编码RNA调控研究进展[J]. 山东大学耳鼻喉眼学报, 2023, 37(5): 135-141. doi: 10.6040/j.issn.1673-3770.0.2022.214 TU Qiaoling, LI Yufeng, PENG Jun. Advances in anti-PD-L1/PD-1 therapy and non-coding RNA regulation in nasopharyngeal carcinoma[J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2023, 37(5): 135-141. doi: 10.6040/j.issn.1673-3770.0.2022.214 [7] Liang TS, Zheng YJ, Wang J, et al. MicroRNA-506 inhibits tumor growth and metastasis in nasopharyngeal carcinoma through the inactivation of the Wnt/β-catenin signaling pathway by down-regulating LHX2[J]. J Exp Clin Cancer Res, 2019, 38(1): 97. doi:10.1186/s13046-019-1023-4 [8] Zhang XF, Zheng RN, Jiang LJ, et al. MiR-331-3p inhibits proliferation and promotes apoptosis of nasopharyngeal carcinoma cells by targeting elf4B-PI3K-AKT pathway[J]. Technol Cancer Res Treat, 2020, 19: 1533033819892251. doi:10.1177/1533033819892251 [9] Zhao YJ, Li C, Zhang Y, et al. CircTMTC1 contributes to nasopharyngeal carcinoma progression through targeting miR-495-MET-eIF4G1 translational regulation axis[J]. Cell Death Dis, 2022, 13(3): 250. doi:10.1038/s41419-022-04686-z [10] Zhu HM, Jiang XS, Li HZ, et al. MiR-184 inhibits tumor invasion, migration and metastasis in nasopharyngeal carcinoma by targeting Notch2[J]. Cell Physiol Biochem, 2018, 49(4): 1564-1576. doi:10.1159/000493459 [11] Luo SD, Tsai HT, Hwang CF, et al. Aberrant miR-874-3p/leptin/EGFR/c-Myc signaling contributes to nasopharyngeal carcinoma pathogenesis[J]. J Exp Clin Cancer Res, 2022, 41(1): 215. doi:10.1186/s13046-022-02415-0 [12] Yu D, Han GH, Zhao X, et al. MicroRNA-129-5p suppresses nasopharyngeal carcinoma lymphangiogenesis and lymph node metastasis by targeting ZIC2[J]. Cell Oncol(Dordr), 2020, 43(2): 249-261. doi:10.1007/s13402-019-00485-5 [13] Chen MH, Chen C, Luo HQ, et al. MicroRNA-296-5p inhibits cell metastasis and invasion in nasopharyngeal carcinoma by reversing transforming growth factor-β-induced epithelial-mesenchymal transition[J]. Cell Mol Biol Lett, 2020, 25(1): 49. doi:10.1186/s11658-020-00240-x [14] Xu QL, Luo Z, Zhang B, et al. Methylation-associated silencing of miR-9-1 promotes nasopharyngeal carcinoma progression and glycolysis via HK2[J]. Cancer Sci, 2021, 112(10): 4127-4138. doi:10.1111/cas.15103 [15] Jiang C, Li L, Xiang YQ, et al. Epstein-barr virus miRNA BART2-5p promotes metastasis of nasopharyngeal carcinoma by suppressing RND3[J]. Cancer Res, 2020, 80(10): 1957-1969. doi:10.1158/0008-5472.CAN-19-0334 [16] Li MY, Huang HP, Cheng FW, et al. MiR-141-3p promotes proliferation and metastasis of nasopharyngeal carcinoma by targeting NME1[J]. Adv Med Sci, 2020, 65(2): 252-258. doi:10.1016/j.advms.2020.03.005 [17] Huang SJ, Ma G, Wang RF, et al. MicroRNA-142-5p promotes the proliferation and metastasis of nasopharyngeal carcinoma[J]. Nucleosides Nucleotides Nucleic Acids, 2023, 42(8): 657-670. doi:10.1080/15257770.2023.2182887 [18] Han JB, Huang ML, Li F, et al. MiR-214 mediates cell proliferation and apoptosis of nasopharyngeal carcinoma through targeting both WWOX and PTEN[J]. Cancer Biother Radiopharm, 2020, 35(8): 615-625. doi:10.1089/cbr.2019.2978 [19] Zhao YG, Gu X, Wang YP. MicroRNA-103 promotes nasopharyngeal carcinoma through targeting TIMP-3 and the Wnt/β-catenin pathway[J]. Laryngoscope, 2020, 130(3): E75-E82. doi:10.1002/lary.28045 [20] He HP, Liao XH, Yang QM, et al. MicroRNA-494-3p promotes cell growth, migration, and invasion of nasopharyngeal carcinoma by targeting Sox7[J]. Technol Cancer Res Treat, 2018, 17: 1533033818809993. doi:10.1177/1533033818809993 [21] Zheng YQ, Bai YF, Yang S, et al. MircoRNA-629 promotes proliferation, invasion and migration of nasopharyngeal carcinoma through targeting PDCD4[J]. Eur Rev Med Pharmacol Sci, 2019, 23(1): 207-216. doi:10.26355/eurrev_201901_16766 [22] Yan HL, Li L, Li SJ, et al. MiR-346 promotes migration and invasion of nasopharyngeal carcinoma cells via targeting BRMS1[J]. J Biochem Mol Toxicol, 2016, 30(12): 602-607. doi:10.1002/jbt.21827 [23] Chen C, Lu ZH, Yang J, et al. MiR-17-5p promotes cancer cell proliferation and tumorigenesis in nasopharyngeal carcinoma by targeting p21[J]. Cancer Med, 2016, 5(12): 3489-3499. doi:10.1002/cam4.863 [24] Huang QL, Hou S, Zhu XQ, et al. MicroRNA-192 promotes the development of nasopharyngeal carcinoma through targeting RB1 and activating PI3K/AKT pathway[J]. World J Surg Oncol, 2020, 18(1): 29. doi:10.1186/s12957-020-1798-y [25] Wan XX, Yi H, Qu JQ, et al. Integrated analysis of the differential cellular and EBV miRNA expression profiles in microdissected nasopharyngeal carcinoma and non-cancerous nasopharyngeal tissues[J]. Oncol Rep, 2015, 34(5): 2585-2601. doi:10.3892/or.2015.4237 [26] Lu TZ, Guo QJ, Lin KY, et al. Circulating Epstein-Barr virus microRNAs BART7-3p and BART13-3p as novel biomarkers in nasopharyngeal carcinoma[J]. Cancer Sci, 2020, 111(5): 1711-1723. doi:10.1111/cas.14381 [27] Liu X, Luo HN, Tian WD, et al. Diagnostic and prognostic value of plasma microRNA deregulation in nasopharyngeal carcinoma[J]. Cancer Biol Ther, 2013, 14(12): 1133-1142. doi:10.4161/cbt.26170 [28] Zhuo XL, Zhou W, Li DR, et al. Plasma microRNA expression signature involving miR-548q, miR-630 and miR-940 as biomarkers for nasopharyngeal carcinoma detection[J]. Cancer Biomark, 2018, 23(4): 579-587. doi:10.3233/CBM-181852 [29] Wu LR, Zheng KX, Yan C, et al. Genome-wide study of salivary microRNAs as potential noninvasive biomarkers for detection of nasopharyngeal carcinoma[J]. BMC Cancer, 2019, 19(1): 843. doi:10.1186/s12885-019-6037-y [30] Lin C, Lin KY, Zhang B, et al. Plasma epstein-barr virus microRNA BART8-3p as a diagnostic and prognostic biomarker in nasopharyngeal carcinoma[J]. Oncologist, 2022, 27(4): e340-e349. doi:10.1093/oncolo/oyac024 [31] Ruan Q, Yang XZ, Zhu L, et al. High miR-3650 expression in nasopharyngeal carcinoma and its clinical prognostic values[J]. Pathol Res Pract, 2021, 224: 153506. doi:10.1016/j.prp.2021.153506 [32] Zhu L, Ni ZG, Liang K, et al. The mechanism of miR-410-3p and miR-34c in nasopharyngeal carcinoma development and progression[J]. Cell Mol Biol, 2021, 67(2): 114-120. doi:10.14715/cmb/2021.67.2.17 [33] Zhang T, Tang Y, Jin Y, et al. Downregulation of miRNA-429 and upregulation of SOX2 were unfavorable to the prognosis of nasopharyngeal carcinoma[J]. Eur Rev Med Pharmacol Sci, 2020, 24(16): 8402-8407. doi:10.26355/eurrev_202008_22637 [34] 王中卫, 杨林, 郭亚, 等. 鼻咽癌患者miR-429、miR-200C表达与预后关系分析[J]. 山东大学耳鼻喉眼学报, 2021, 35(3): 81-86. doi: 10.6040/j.issn.1673-3770.0.2020.016 WANG Zhongwei, YANG Lin, GUO Ya, et al. Analysis of the relationship between miR-429 and miR-200C expression and prognosis in patients with nasopharyngeal carcinoma[J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2021, 35(3): 81-86. doi: 10.6040/j.issn.1673-3770.0.2020.016 [35] Zhong JH, Zhong JJ, Shi YN, et al. Prognostic potentials of miRNA-19a-3p and PDCD5 in nasopharynx carcinoma[J]. Eur Rev Med Pharmacol Sci, 2020, 24(21): 11114-11119. doi:10.26355/eurrev_202011_23598 [36] Zhou XQ, Zheng L, Zeng CY, et al. MiR-302c-5p affects the stemness and cisplatin resistance of nasopharyngeal carcinoma cells by regulating HSP90AA1[J]. Anticancer Drugs, 2023, 34(1): 135-143. doi:10.1097/CAD.0000000000001392 [37] Zhao YY, Wang PH, Wu QW. MiR-1278 sensitizes nasopharyngeal carcinoma cells to cisplatin and suppresses autophagy via targeting ATG2B[J]. Mol Cell Probes, 2020, 53: 101597. doi:10.1016/j.mcp.2020.101597 [38] Li JX, Hu CQ, Chao H, et al. Exosomal transfer of miR-106a-5p contributes to cisplatin resistance and tumorigenesis in nasopharyngeal carcinoma[J]. J Cell Mol Med, 2021, 25(19): 9183-9198. doi:10.1111/jcmm.16801 [39] Chen J, Lu FK, Hu CM. MicroRNA-299 targets VEGFA and inhibits the growth, chemosensitivity and invasion of human nasopharyngeal carcinoma cells[J]. J BUON, 2019, 24(5): 2049-2055 [40] Peng XW, Cao PG, Li JJ, et al. MiR-1204 sensitizes nasopharyngeal carcinoma cells to paclitaxel both in vitro and in vivo[J]. Cancer Biol Ther, 2015, 16(2): 261-267. doi:10.1080/15384047.2014.1001287 [41] Wan FZ, Chen KH, Sun YC, et al. Exosomes overexpressing miR-34c inhibit malignant behavior and reverse the radioresistance of nasopharyngeal carcinoma[J]. J Transl Med, 2020, 18(1): 12. doi:10.1186/s12967-019-02203-z [42] Jiang JH, Tang Q, Gong JE, et al. Radiosensitizer EXO-miR-197-3p inhibits nasopharyngeal carcinoma progression and radioresistance by regulating the AKT/mTOR axis and HSPA5-mediated autophagy[J]. Int J Biol Sci, 2022, 18(5): 1878-1895. doi:10.7150/ijbs.69934 [43] Tang J, Liu ZY, Tang Y, et al. Effects of Dicer1 targeted by EBV-miR-BART6-5p on biological properties and radiosensitivity of nasopharyngeal carcinoma[J]. Hum Exp Toxicol, 2021, 40(6): 977-993. doi:10.1177/0960327120979020 [44] Zhan SQ, Ni BL. Hsa-miR-9-5p down-regulates HK2 and confers radiosensitivity to nasopharyngeal carcinoma[J]. Technol Cancer Res Treat, 2021, 20: 1533033821997822. doi:10.1177/1533033821997822 [45] Deng LQ, Yin Q, Liu SY, et al. MicroRNA-613 enhances nasopharyngeal carcinoma cell radiosensitivity via the DNA methyltransferase 3B/Tissue inhibitor of matrix metalloproteinase-3/signal transducer and activator of transcription-1/forkhead box O-1 axis[J]. Dis Markers, 2022: 5699275. doi:10.1155/2022/5699275 |
| [1] | 邱前辉,肖旭平,杨钦泰,叶菁,邓泽义,王德生,谭国林,蒋卫红,卢永田,唐隽,石照辉,邓晓聪,刘遗斌,王跃武,段传志,杜德坤,白小欣,陈文伙,莫立根,蔡楚伟,曾鹏,何旭英,杨一梅,赵洲洋,陈健龙,赵充,林志雄,李先明,李曙平,陈冬平,陈勇,黄莹,陈春燕,韩非,黄理金,瞿申红. 鼻咽癌治疗后并发颈动脉爆裂综合征的临床处理专家共识[J]. 山东大学耳鼻喉眼学报, 2025, 39(4): 1-18. |
| [2] | 王思权,朱洪申,张晓斌,赵洲洋,马跃,杨一梅,黄理金. 放射治疗后鼻咽癌患者单侧颈内动脉栓塞术后脑卒中及颅神经麻痹的相关因素分析[J]. 山东大学耳鼻喉眼学报, 2025, 39(4): 19-25. |
| [3] | 黄巧,任毅,侯涛,廖行伟,朱子昂,詹晓琳,刘盈,尹时华. 鼻咽癌组织中EphB2表达及与临床病理特征的相关性[J]. 山东大学耳鼻喉眼学报, 2025, 39(4): 26-30. |
| [4] | 孙春晓,王文晴,岳田,刘济生. 高低累积顺铂剂量同步放化疗治疗鼻咽癌的疗效分析[J]. 山东大学耳鼻喉眼学报, 2025, 39(4): 31-41. |
| [5] | 徐飞,朱光熹,王可心. 基于决策树算法构建鼻咽癌患者放疗后发生放射性口腔黏膜炎风险的预测模型[J]. 山东大学耳鼻喉眼学报, 2025, 39(4): 42-48. |
| [6] | 王再兴,唐志元,李定波,石照辉,曾宪海,张秋航. 鼻咽癌放疗后肿瘤复发及颅底骨坏死引起颈内动脉破裂的治疗方案[J]. 山东大学耳鼻喉眼学报, 2025, 39(4): 49-58. |
| [7] | 孙芳,谢楚波,邱前辉. 营养指标对鼻咽癌放射性颅底坏死患者创面修复影响的回顾性分析[J]. 山东大学耳鼻喉眼学报, 2025, 39(4): 59-68. |
| [8] | 朱瑞楷,吴家荣,孙芳,谢楚波,邱前辉. 基于计算机断层扫描血管造影术评估鼻咽癌放疗后引起颈内动脉狭窄状况及其影响因素的研究[J]. 山东大学耳鼻喉眼学报, 2025, 39(4): 77-84. |
| [9] | 覃德波,薛建成,杨文月,胡兵,陈涛,俞艳萍,孟庆国,孙焕吉,苗北平,卢永田. 鼻咽癌诊疗变革:生物标志物与鼻内镜手术协同推进早期治疗发展[J]. 山东大学耳鼻喉眼学报, 2025, 39(4): 85-92. |
| [10] | 吴家荣,邱前辉. 颅底筋膜组织在早期复发性鼻咽癌内镜手术中的临床意义[J]. 山东大学耳鼻喉眼学报, 2025, 39(4): 108-113. |
| [11] | 杨鸣,刘雪霞,张华. m6A识别蛋白IGF2BPs家族在头颈肿瘤中的研究进展[J]. 山东大学耳鼻喉眼学报, 2025, 39(3): 153-161. |
| [12] | 吴敏,李正阳,孟杰,叶惠平. 程序性细胞死亡的分子机制和其在鼻咽癌中的作用[J]. 山东大学耳鼻喉眼学报, 2025, 39(2): 152-157. |
| [13] | 周荷青,申琪. 中医药治疗变应性鼻炎疗效的生物标志物研究进展[J]. 山东大学耳鼻喉眼学报, 2025, 39(2): 168-176. |
| [14] | 张茂华,魏日富,朱忠寿,刘平,高尚,李慧凤. LncRNA PCAT-1对鼻咽癌细胞生物学行为及化疗敏感性的影响[J]. 山东大学耳鼻喉眼学报, 2025, 39(1): 68-76. |
| [15] | 张杉,陈秋,周方伟,马亦飞. 生物标志物在咽喉反流性疾病中的研究进展[J]. 山东大学耳鼻喉眼学报, 2024, 38(6): 46-54. |
|
||